Vergoeding 2020-2024 voor ATC-subgroep A10BJ : Glucagonachtig peptide-1-agonisten (glp-1-agonisten)
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| A10BJ01 Exenatide | 588.730 | 478.400 | 358.640 | 43.260 | 21.559 |
| A10BJ02 Liraglutide (Saxenda ®) | 11.639.700 | 9.275.700 | 17.715.000 | 26.717.900 | 30.199.000 |
| A10BJ03 Lixisenatide (Lyxumia ®) | 65.620 | 42.772 | 35.858 | 44.530 | 2.875 |
| A10BJ05 Dulaglutide (Trulicity ®) | 3.587.500 | 4.413.300 | 7.322.800 | 7.084.200 | 5.225.000 |
| A10BJ06 Semaglutide (Ozempic ®) | 24.173.000 | 36.169.000 | 55.062.900 | 83.464.600 | 114.267.000 |
| Totaal | 40.054.550 | 50.379.172 | 80.495.198 | 117.354.490 | 149.715.434 |